Facing Aricept Expiration, Eisai Maximizes Product Value
This article was originally published in PharmAsia News
Executive Summary
Eisai is speeding up the launch of a new high-dose Aricept (donepezil) to maximize product value as the Alzheimer's disease drug will lose patent protection at the end of this month
|
Eisai is speeding up the launch of a new high-dose Aricept (donepezil) to maximize product value as the Alzheimer's disease drug will lose patent protection at the end of this month. The company has obtained the marketing approval for Aricept 23mg in July, and started a full promotion in the U.S. Eisai is also collaborating with partner Pfizer to develop a generic Aricept, aiming to launch it ahead of other generic makers. Aricpet 5mg and 10mg tablets are set to go off patent protection Nov. 25 and Indian generic drug maker Ranbaxy has obtained U.S. approval for generic Aricept. (Click here for more - Japanese language) "Eisai Fends Off Generics As Aricept Expires" - Chemical Daily (11/11/2010) |